medigraphic.com
Instituto Nacional de Salud Pública

2016, Number 2

<< Back Next >>

salud publica mex 2016; 58 (2)

Genetic polymorphisms of PPAR gamma, arsenic methylation capacity and breast cancer risk in Mexican women

Pineda-Belmontes CP, Hernández-Ramírez RU, Hernández-Alcaraz C, Cebrián ME, López-Carrillo L

Language: English
References: 36
Page: 220-227
PDF size: 258.24 Kb.


ABSTRACT

Objective. To evaluate whether the presence of polymorphisms of peroxisome proliferator-activated receptor gamma PPARγ (Pro12Ala) and PPARGC1B (Ala203Pro) modifies the association between the inorganic arsenic (iAs) methylation capacity and breast cancer (BC). Materials and methods. Mexican women were interviewed, and blood and urine samples were collected from them (cases/controls= 197/220). The concentration of urinary arsenic species and the polymorphisms of interest were determined by high-performance liquid chromatography with inductively coupled plasma mass spectrometry (HPLC-ICP-MS) and polymerase chain reaction (PCR), respectively. Results. In women with a high %MMA (urinary monomethyl arsenic) and high primary methylation ratio (PM = MMA/iAs), the risk of BC was increased (odds ratio [OR]%MMA T3vs.T1= 3.60: 95% confidence interval [CI] 2.02-6.41, ORPMI T3vs.T1= 3.47: 95%CI 1.95-6.17), which was maintained after adjusting for polymorphisms. No significant interactions were observed between the polymorphisms and the arsenic variables on the risk of BC. Conclusion. Pro12Ala and Ala203Pro polymorphisms did not modify the association between the iAs methylation capacity and BC.


REFERENCES

  1. Tachibana K, Yamasaki D, Ishimoto K, Doi T. Review article: The role of PPARs in cancer. Hindawi Publishing Corporation 2008;1-15.

  2. Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ. Terminal differentiation of human breast cancer through PPARγ. Mol Cell 1998;1:465-470.

  3. Wu M, Chu C, Chou Y, Chou W, Yang T, Hsu G et al. Joint effect of peroxisome proliferator-activated receptor gamma genetic polymorphisms and estrogen-related risk factor on breast cancer risk: results from a casecontrol study in Taiwan. Breast Cancer Res Treat 2011;127:777-784.

  4. Grommes C, Landreth GE, Heneka MT. Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncol 2004;5:419-429.

  5. Dong J. Anticancer activities of PPAR gamma in breast cancer are context-dependent. Am J Pathol 2013;182:1972-1973.

  6. Tontonoz P, Spiegelman B. Fat and beyond: the diverse biology of PPAR gamma. Annu Rev Biochem 2008;77:289-312.

  7. Wirtenberger M, Tchatchou S, Hemminki K, Schmutahard J, Sutter C, Schumutzler R, et al. Associations of genetic variants in the estrogen receptor coactivators PPARGC1A, PPARGC1B y EP300. Carcinogenesis 2006;27:2201-2208.

  8. Memisoglu A, Hankinson SE, Manson JE, Colditz JA, Hunter DJ. Lack of association of the codon 12 polymorphism of the peroxisome proliferator- activated receptor gamma genne with breast cancer and body mass. Pharmacogenetics 2002;12:597-603.

  9. Wang Y, McCullough M, Stevens V, Rodriguez C, Jacobs E, Teras L, et al. Nested case-control study of energy regulation candidate gene single nucleotide polumorhisms and breast cancer. Anticancer Res 2007;27:589-593.

  10. Li Y, Li Y, Wedren S, Li G, Charn TH, Desai KV, et al. Genetic variation of ESR1 and its co-activator PPARGC1B is synergistic in augmenting the risk of estrogen receptor-positive breast cancer. Breast Cancer Res 2011;13:1-12.

  11. Martínez-Nava GA, Burguete-García AI, López-Carrillo L, Hérnandez- Ramírez RU, Madrid-Marina V, Cebrián ME. PPARγ y PPARG1CB polymorphisms modify the association between phthalate metabolites and breast cancer risk. Biomarkers 2013;18:493-501.

  12. Cebrián ME, Albores A, García-Vargas G, Del Razo LM. Chronic arsenic poisoning in humans. The case of Mexico. Arsenic in the environment part II: Human health and ecosystem effects. New York: John Wiley & Sons, 1994.

  13. Del Razo LM, García-Vargas GG, García-Salcedo J, Sanmiguel MF, Rivera M, Hernández MC, Cebrián ME. Arsenic levels in cooking food and assessment of adult dietary intake of arsenic in the Region Lagunera, Mexico. Food Chem Toxicol 2002; 40:1423-1431.

  14. López-Carrillo L, Hérnandez-Ramírez RU, Gandolfi AJ, Ornelas-Aguirre JM, Torres-Sánchez L, Cebrián ME. Arsenic methylation capacity is associated with breast cancer in northern Mexico. Toxicological and Applied Pharmacology 2014;280:53-59.

  15. Torres-Sánchez LE, Rojas-Martínez R, Escamilla-Núñez C, de la Vara- Salazar E, Lazcano-Ponce E. Tendencias en la mortalidad por cáncer en México de 1980 a 2011. Salud Publica Mex 2014;56:473-491.

  16. Ruiz-Ramos R, López-Carrillo L, Ríos-Pérez AD, Vizcaya-Ruíz AD, Cebrián ME. Sodium arsenate induces ROS generation, DNA oxidative damage, HO-1 and c-Myc proteins, NF-kB activation and cell proliferation in human breast cancer MCF-7 cells. Elsevier 2009;674:109-115.

  17. Wauson E, Langan A, Vorce R. Sodium arsenite inhibits and reserves expresion of adipogenic and fat cell-specific genes during in vitro adipogenesis. Toxicol Sci 2002;65:211-219.

  18. Yadav S, Anbalagan M, Shi Y, Wang F, Wang H. Arsenic inhibits the adipogenic differentiation of mesenchymal stem cells by down-regulating peroxisome proliferator-activated receptor gamma and CCAAT enhancer- binding proteins. Toxilogic in vitro 2012;27:211-219.

  19. Xu Y, Tokar E, Waalkes M. Arsenic-induced cancer cell phenotype in human breast epithelia is strogen receptor-independent but involves aromatase activation. Arch Toxicol 2013;88:263-274.

  20. Margalit O, Wang D, DuBois RN. PPARγ agonists target aromatase via both PGE2 and BRCA1. Cancer Pres Res 2012;5:1169-1172.

  21. Amadou A, Torres-Mejía G, Hainaut P, Romieu I. Brest cancer in Latin America: global burden, patterns, and risk factors. Salud Publica Mex 2014;56:547-554.

  22. Gilbert-Diamond D, Cottingham KL, Gruber JF, Punshon T, Sayarath V, Gandolfi AJ, et al. Rice consumption contributes to arsenic exposure in US women. PNAS 2011;108: 20656-20660.

  23. Barr D, Landsittel D, Nishioka M, Thomas K, Curwin T, Raymer J, et al. A Survey of Laboratory and Statistical Issues Related to Farmworker Exposure Studies. Environ Health Perspect 2006;114:961-968.

  24. Randox. Manual RX Monza Técnicas Randox [internet monography]. Reino Unido, 2010 [consulted 2014 October] Available at: http://sistemainterno. com/web/wp-content/themes/aaaclientesflash/gaamsa2011/pdf/ MANUAL_QC_2013.pdf

  25. Mao Q, Guo H, Gao L, Wang H, Ma X. Peroxisome proliferator-activated receptor γ2 Pro12Ala (rs1801282) polymorphism and breast cancer susceptibility: a meta-analysis. Mol Med Rep 2013;8:1773-1778.

  26. Vogel U, Christensen J, Nexø BA, Wallin H, Friis S,Tjønneland A. Peroxisome profilerator-activated receptorg2 Pro12Ala, interaction with alcohol intake and NSAID use, in relation to risk of breast cancer in a prospective study of Danes. Carcinogenesis 2006;28:427-434.

  27. Black MH, Fingerlin TE, Allayee H, Zhang W, Xiang AH, Trigo E, et al. Evidence of interaction between PPARG2 and HNF4A contributing to variation in insulin sensitivity in Mexican Americans. Diabetes 2008;57:1048-1056.

  28. Weitzel J, Lagos V, Blazen K, Nelson R, Ricker C, Herzog J, et al. Prevalence of BRCA mutations and founder effect in high-risk hispanic families. Cancer Epidemiol Biomarkers Prev 2005;14:1666-1671.

  29. Hsueh M, Chiou HY, Huang YL, Wu WL, Huang CC, Yang MH, et al. Serum beta-carotene level, arsenic methylation capability, and incidence of skin cancer. Cancer Epidemiol Biomarkers Prev 1997;6:589-596

  30. Yu RC, Hsu KH, Chen CJ, Froines JR. Arsenic methylation capacity and skin cancer. Cancer Epidemiol Biomarkers Prev 2000;9:1259-1262.

  31. Chen YC, Guo YL, Su HJ, Hsueh YM, Smith TJ, Ryan LM, et al. Arsenic methylation and skin cancer risk in southwestern Taiwan. J Occup Environ Med 2003;45:241-248.

  32. Chen YC, Su HJ, Guo YL, Hsueh YM, Smith TJ, Ryan LM, et al. Arsenic methylation and bladder cancer risk in Taiwan, Cancer Causes Control 2003;14:303-310.

  33. Steinmaus C, Bates MN, Yuan Y, Kalman D, Atallah R, Rey OA, et al. Arsenic methylation and bladder cancer risk in case-control studies in Argentina and the United States. J Occup Environ Med 2003;48:478-488.

  34. Pu YS, Yang SM, Huang YK, Chung CJ, Huang SK, Chiu AW, et al. Urinary arsenic profile affects the risk of urothelial carcinoma even at low arsenic exposure. Toxicol Appl Pharmacol 2007; 218:99-106.

  35. Huang YK, Huang YL, Hsueh YM, Yang MH, Wu MM, Chen SY, et al. Arsenic exposure, urinary arsenic speciation, and the incidence of urothelil carcinoma: a twelve-year follow up study. Cancer Causes Control 2008;19:829-839.

  36. Steinmaus C, Yuan Y, Kalman D, Rey OA, Skibola CF, Dauphine D, et al. Individual differences in arsenic metabolism and lung cancer in a case-control study in Cordoba, Argentina. Toxicol Appl Pharmacol 2010;247:138-145.




2020     |     www.medigraphic.com